QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Stevanato Group S.p.A. (STVN)

Healthcare

No action
Fundamental
3
Sentiment
2
Technical
2

Do Nothing: qualitativeScore is 2 (below the required floor of 3) — the upstream screen carries a moderate red-flag cap (sharp sentiment deterioration with no offsetting bullish catalyst), and no chart pattern overrides that; the chart independently offers no qualifying setup (bounce-only below all major averages), and neither a pullback limit (countertrend: price 14.07 < SMA50 19.38 with MACD -1.73 < 0) nor a breakout stop (no confirmed accumulation above the 14.10 five-session cap) qualifies.

Analysis as of 2026-11-11· more than 2 trading days ago

Company overview

Stevanato Group S.p.A. provides integrated solutions for the pharmaceutical and healthcare sectors, including containment solutions, drug delivery systems, and medical devices. The company also manufactures specialized machinery for visual inspection, assembly, packaging, and glass formation. Founded in 1949, it operates from Piombino Dese, Italy, as a subsidiary of Stevanato Holding S.R.L.

Fundamental

fair
Fundamental3
Mixed fundamentals

Stevanato Group has a solid industrial base but suffers from poor cash conversion and governance issues.

Stevanato Group has a sound, low-leverage balance sheet, positive GAAP earnings, recovering margins and steady mid-single-digit revenue growth, but free cash flow is effectively nil because of a heavy capacity-expansion capex cycle, five-year EPS growth is negative, ROIC has halved, and the FY2025 annual report carries an adverse auditor opinion on internal control over financial reporting that is still unremediated. Valuation has de-rated to roughly 24x earnings and 12x EV/EBITDA with a large gap to analyst targets, but poor cash conversion and concentrated family control keep the overall fundamental picture mixed — a watchlist name rather than an actionable buy.

Sentiment

weak
Sentiment2
Negative sentiment

Recent guidance cuts and analyst downgrades have led to a negative sentiment shift.

Dominant driver is the 2026-11-03 Q3-2026 print and 2027 outlook reset (announced) — GLP-1 revenue down to roughly 17–18% of total with 2027 growth guided to low single digits — which produced a ~24% to ~28.6% one-day repricing and a still-open analyst revision cycle (William Blair cut to Market Perform; UBS target reduced to USD 16 from USD 23), while measured media sentiment deteriorated determinately from a mildly positive baseline (polarity_score ≈ +0.18, n=9) to slightly negative over the last 14 days (≈ -0.10, n=15), a ≈ -0.27 shift, with no market-rewarded bullish counterweight. No severe red flag fired — the seven plaintiff-firm 'investigation' notices are law-firm marketing with zero regulator-confirmed actions — but the moderate red-flag cap applied for sharp sentiment deterioration (≤14d) with no offsetting bullish catalyst, and retail sentiment is indeterminate because Reddit access was blocked (403).

Technical

weak
Technical2
Bounce-only chart

The stock is in a strong downtrend with no qualifying technical setup for action.

Chart quality 2/5: STVN is coiling just above its post-crash low after the 2026-11-03 reset (19.74 prior close to a 14.10 close, -28.6%, on 4.79M shares), but the rebound is a bounce inside an intact downtrend, not a trend repair. Price 14.07 sits below SMA20 17.40, SMA50 19.38, SMA200 17.93, EMA9 14.94 and EMA21 16.77; only the fastest constructs sit at or below price (WMA9 14.07, DEMA14 13.80, TEMA14 13.01), the classic crash-bounce signature. ADX14 40.42 is high and rising which, with price below every average, confirms a strong DOWN trend. MACD remains deeply negative (-1.73/-1.26/-0.47) even though the histogram is contracting from -0.64, and RSI14 28.53 recovering from 19.45 plus Williams %R -76.91 off its -86.74 low describe decelerating downside momentum, not a reversal. No tradable setup exists, and the qualitative floor (score 2 < 3) independently routes the action to Do Nothing.

You’re looking at 2026-11-11 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.